natgillin/translations-raw huggingface dataset:
The compound or therapeutically acceptable salt of any one of claims 1-10, and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent, for use in treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, a lymphoid malignancy of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer or spleen cancer. 
Spoj ili terapijski prihvatljiva sol u skladu s bilo kojim od patentnih zahtjeva 1-10 i terapijski učinkovita količina jednog dodatnog terapijskog sredstva ili više od jednog dodatnog terapijskog sredstva, naznačen time, da je za uporabu u liječenju raka mokraćnog mjehura, raka mozga, raka dojke, raka koštane srži, raka maternice, kronične limfocitne leukemije, raka debelog crijeva, raka jednjaka, raka jetre, limfoblastične leukemije, folikularnih limfoma, limfne malignosti stanica podrijetla T ili B, melanoma, mijelogene leukemije, mijeloma, raka usne šupljine, raka jajnika, raka pluća ne-malih stanica, raka prostate, raka pluća malih stanica ili raka slezene.
characterized in that the mobile device comprises an active transmit circuit (2130) coupled between the smartcard controller (330) and the transmit antenna (1752) that in operation forms a signal that mimics the at least one of the frequency sideband and wherein the signal drives the transmit antenna (1752). 
naznačeni time da se navedena RFID kartica sastoji od aktivnog odašiljačkog sklopa (2130) spojenog između kontrolera pametne kartice (330) i odašiljačke antene (1752) koja pri radu stvara signal koji oponaša najmanje jedan frekvencijski pojas, pri čemu signal pokreće odašiljačku antenu (1752).
The mobile device of claim 1 wherein the transmit antenna and receive antenna are one antenna (1542). 
RFID kartica iz zahtjeva 1, pri čemu su odašiljačka i prijemna antena jedna antena (1542).
The mobile device of claim 1 or 2 wherein the smartcard controller includes a pad (2410) coupled to the active transmit circuit (2130) to provide digital data to the active transmit circuit (2130). 
RFID kartica iz zahtjeva 1 ili 2, pri čemu kontroler pametne kartice uključuje podlogu (2410) spojenu na aktivni odašiljački sklop (2130) kako bi isti primio digitalne podatke.
A nutritional composition according to any one of the preceding claims for use in one or more selected from prevention of obesity, reducing the risk of obesity, treatment of obesity, prevention of diabetes type 2, reducing the risk of occurrence of insulin resistance and improving insulin sensitivity, preventing metabolic syndrome, preventing osteopenia and/or osteoporosis. 
Nutritivni pripravak prema bilo kojem od prethodnih zahtjeva za uporabu u jednom ili više odabranog između prevencije pretilosti, smanjenja rizika od pretilosti, liječenja pretilosti, prevencije dijabetesa tipa 2, smanjenja rizika od pojave inzulinske rezistencije i poboljšanja osjetljivosti na inzulin, prevencije metaboličkog sindroma, prevencije osteopenije i/ili osteoporoze.
A nutritional composition according to any one of claims 1-9 for use in improving body composition, the improvement of body composition being selected from the group consisting of increased lean body mass, decreased fat mass relative to total body weight, decreased visceral fat mass relative to total body weight, a decreased visceral fat mass relative to total fat mass, decreased fat accumulation and increased muscle mass, increased bone mass and increased bone mineral density. 
Nutritivni pripravak prema bilo kojem od zahtjeva 1-13 za uporabu u poboljšanju tjelesne građe, poboljšanje tjelesne građe se odabire iz skupine koju čine povećanje nemasnog dijela tjelesne težine, smanjenje masne težine u odnosu na ukupnu tjelesnu težinu, smanjenje tkivne masne težine tkiva u odnosu na ukupnu tjelesnu težinu, smanjenje tkivne masne težine tkiva u odnosu na ukupnu masnu težinu, smanjenje nakupljanja masti i povećanje mišićne mase, povećanje koštane mase i povećanje mineralne gustoće kostiju.
A process for the manufacture of a nutritional composition according to claims 1 to 9 comprising preparing an aqueous phase comprising protein and digestible carbohydrates and preparing a fat phase comprising lipids, wherein phospholipids are present in the aqueous and/or fat phase, wherein the fatty acid composition of the lipid comprises linoleic acid and alpha-linolenic acid in a weight ratio of 2 to 10, wherein the fatty acid composition of the lipid comprises at least 10 wt.% palmitic acid based on total fatty acids, and at least 15 wt.% of the palmitic acid is esterified to the sn-2 position of a triglyceride based on total palmitic acid, mixing the fat and aqueous phase and homogenizing the mixture of fat and aqueous phase into an oil-in-water emulsion with lipid globules at least partly coated on the surface with phospholipids, the amount of phospholipids present in the nutritional composition being from 0.5 to 20 wt.% phospholipids based on total lipid. 
Postupak proizvodnje nutritivnog pripravka prema zahtjevima 1 do 13 koji obuhvaća pripremu vodene faze koja sadrži proteine i probavljive ugljikohidrate te pripremu masne faze koja sadrži lipide, gdje su fosfolipidi prisutni u vodenoj i/ili masnoj fazi, gdje sastav masnih kiselina unutar lipida obuhvaća linolensku kiselinu i alfa-linolensku kiselinu u težinskom omjeru od 2 do 10, gdje sastav masnih kiselina unutar lipida obuhvaća barem 10 tež.% palmitinske kiseline u odnosu na ukupne masne kiseline i barem 30 tež.% te ukupne palmitinske kiseline je esterificirano na sn-2 položaju triglicerida, zatim miješanje masne i vodene faze te homogeniziranje smjese masne i vodene faze u emulziju tipa ulje-u-vodi s lipidnim globulama koje su barem djelomično obložene fosfolipidima na površini, količina fosfolipida prisutnih u nutritivnom pripravku je od 0.5 do 20 tež.% fosfolipida u odnosu na ukupne lipide.
Colloidal solution as basis for a foam spray formulation comprising 
Koloidna otopina kao osnova za formulaciju pjene za raspršivanje koja sadrži
at least one active ingredient, 
barem jedan aktivni sastojak,
at least one membrane-forming molecule, and 
barem jednu molekulu koja tvori membranu, i
Colloidal solution of claim 1 wherein the particle size is less equal than 100 nm. 
Koloidna otopina prema zahtjevu 1 naznačena time da je veličina čestica manja ili jednaka 100 nm.
Process of claim 9 wherein a solution comprising at least parts of the active ingredient, at least one membrane-forming molecule, water as solvent, ethanol as solubilizer and a surfactant is added to a mixture containing a buffering agent, a preservative, a chelating agent, a solvent and the active ingredient. 
Postupak prema zahtjevu 9 naznačen time da otopina sadrži barem dijelove aktivnog sastojka, barem jednu molekulu koja tvori membranu, vodu kao otapalo, etanol kao pospješivač topivosti i surfaktant se dodaju u smjesu koja sadrži pufersko sredstvo, konzervans, sredstvo za tvorbu kelata, otapalo i aktivni sastojak.
Colloidal solution of any of claims 1 to 8 for treating atopic dermatitis, psoriasis, contact eczema, skin allergies, skin inflammation due to insect bites, skin allergies, senile pruritus, minor bums and sunburns, or irritated skin. 
Koloidna otopina prema bilo kojem od zahtjeva 1 do 8 naznačena time da je za liječenje atopijskog dermatitisa, psorijaze, kontaktnog ekcema, alergija kože, upala kože zbog uboda insekata, kožnih alergija, senilnog svrbeža, manjih opeklina i opeklina od sunca, ili nadražene kože.
A compound selected from the group consisting of; 
Spoj odabran iz skupine koju čine;
The compound of claim 1, wherein the compound is 1-((6-(trans-4-tert-butylcyclohexyloxy)quinazolin-2-yl)methyl)piperidine-4-carboxylic acid or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-((6-(trans-4-tert-butilcikloheksiloksi)kinazolin-2-il)metil)piperidin-4-karboksilna kiselina ili njegova farmaceutski prikladna sol.
The compound of claim 1, wherein the compound is 1-(1-(6-(trans-4-tert-butylcyclohexyloxy)naphthalen-2-yl)-2,2,2-trifluoroethyl)piperidine-4-carboxylic acid or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-(1-(6-(trans-4-tert-butilcikloheksiloksi)naftalen-2-il)-2,2,2-trifluoroetil) piperidin-4-karboksilna kiselina ili njegova farmaceutski prikladna sol.
The compound of claim 1, wherein the compound is 1-((6-(spiro[4.5]decan-8-yloxy)naphthalen-2-yl)methyl)piperidine-4-carboxylic acid or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-((6-(spiro[4.5]dekan-8-iloksi)naftalen-2-il)metil)piperidin-4-karboksilna kiselina ili njegova farmaceutski prikladna sol.
The compound of claim 1, wherein the compound is 1-((6-(cis-4-ethylcyclohexyloxy)naphthalen-2-yl)methyl)piperidine-4-carboxylic acid or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-((6-(cis-4-etilcikloheksiloksi)naftalen-2-il)metil)piperidin-4-karboksilna kiselina ili njegova farmaceutski prikladna sol.
The compound of claim 1, wherein the compound is 1-((2-(trans-4-tert-butylcyclohexyloxy)quinolin-6-yl)methyl)piperidine-4-carboxylic acid or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-((2-(trans-4-tert-butilcikloheksiloksi)kinolin-6-il)metil)piperidin-4-karboksilna kiselina ili njegova farmaceutski prikladna sol.
The compound of claim 1, wherein the compound is 1-(6-(trans-4-tert-butylcyclohexyloxy)-2-naphthoyl)piperidine-4-carboxylic acid or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-(6-(trans-4-tert-butilcikloheksiloksi)-2-naftoil)piperidin-4-karboksilna kiselina ili njegova farmaceutski prikladna sol.
The compound of claim 1, wherein the compound is 1-((6-((4-tert-butylcyclohexylidene)methyl)naphthalen-2-yl)methyl)piperidine-4-carboxylic acid or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-((6-((4-tert-butilcikloheksiliden)metil)naftalen-2-il)metil)piperidin-4-karboksilna kiselina ili njegova farmaceutski prikladna sol.
The compound of claim 1, wherein the compound is 1-[6-(4-tert-butyl-cyclohexyloxy)-naphthalen-2-ylmethyl]-3-methyl-piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-[6-(4-tert-butil-cikloheksiloksi)-naftalen-2-ilmetil]-3-metil-piperidin-4-karboksilna kiselina, ili njegova farmaceutski prikladna sol.
The compound of claim 1, wherein the compound is 1-[6-(4-tert-butyl-cyclohexyloxy)-naphthalen-2-ylmethyl]-4-phenyl-piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-[6-(4-tert-butil-cikloheksiloksi)-naftalen-2-ilmetil]-4-fenil-piperidin-4-karboksilna kiselina, ili njegova farmaceutski prikladna sol.
The compound of claim 1, wherein the compound is 1-[6-(4-tert-butyl-cyclohexyloxy)-naphthalen-2-ylmethyl]-perhydro-azepine-4-carboxylic acid or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-[6-(4-tert-butil-cikloheksiloksi)-naftalen-2-ilmetil]-perhidro-azepin-4-karboksilna kiselina ili njegova farmaceutski prikladna sol.
The compound of claim 1, wherein the compound is 1-[7-(trans-4-tert-butyl-cyclohexyloxy)-isoquinolin-3-ylmethyl]-piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-[7-(trans-4-tert-butil-cikloheksiloksi)-izokinolin-3-ilmetil]-piperidin-4-karboksilna kiselina, ili njegova farmaceutski prikladna sol.
The compound of claim 1, wherein the compound is 1-((6-(cyclopentyloxy)naphthalen-2-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-((6-(ciklopentiloksi)naftalen-2-il)metil)piperidin-4-karboksilna kiselina, ili njegova farmaceutski prikladna sol.
The compound of claim 1, wherein the compound is 1-((6-(tetrahydro-2H-pyran-4-yloxy)naphthalen-2-yl)methyl)piperidine-4-carboxylic acid or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-((6-(tetrahidro-2H-piran-4-iloksi)naftalen-2-il)metil)piperidin-4-karboksilna kiselina ili njegova farmaceutski prikladna sol.
The compound of claim 1, wherein the compound is 1-[6-(4-tert-butyl-cyclohexyloxy)-naphthalen-2-ylmethyl]-piperidine-2-carboxylic acid, or a pharmaceutically acceptable salt thereof. 
Spoj prema zahtjevu 1, gdje je spoj 1-[6-(4-tert-butil-cikloheksiloksi)-naftalen-2-ilmetil]-piperidin-2-karboksilna kiselina, ili njegova farmaceutski prikladna sol.
A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt of any one of claims 1 to 18, and a pharmaceutically acceptable excipient or carrier. 
Farmaceutski pripravak koji sadrži spoj ili farmaceutski prikladnu sol prema bilo kojem od zahtjeva 1 do 18, i farmaceutski prikladnu pomoćnu tvar ili nosač.
The compound or pharmaceutically acceptable salt of any one of claims 1 to 18, for use in a method for prevention or treatment of a neurologic disease in a mammal. 
Spoj ili farmaceutski prikladna sol prema bilo kojem od zahtjeva 1 do 18, za uporabu u postupku prevencije ili liječenja neurološke bolesti u sisavca.
The compound or pharmaceutically acceptable salt for use according to claim 20, wherein the neurologic disease is Alzheimer's disease, Parkinson's disease, Huntington's disease, a motor neuron disease, amyotrophic lateral sclerosis, multiple sclerosis, neuronal trauma, or cerebral ischemia. 
Spoj ili farmaceutski prikladna sol za uporabu prema zahtjevu 20, gdje je neurološka bolest Alzheimerova bolest, Parkinsonova bolest, Huntingtonova bolest, bolest motornih neurona, amiotrofična lateralna skleroza, multipla skleroza, neuronalna trauma, ili cerebralna ishemija.
The compound or pharmaceutically acceptable salt of any one of claims 1 to 18, for use in a method for prevention or treatment of neuropathic pain in a mammal. 
Spoj ili farmaceutski prikladna sol prema bilo kojem od zahtjeva 1 do 18, za uporabu u postupku prevencije ili liječenja neuropatske boli u sisavca.
The compound or pharmaceutically acceptable salt of any one of claims 1 to 18, for use in a method for prevention or treatment of an autoimmune disease in a mammal. 
Spoj ili farmaceutski prikladna sol prema bilo kojem od zahtjeva 1 do 18, za uporabu u postupku prevencije ili liječenja autoimune bolesti u sisavca.
The compound or pharmaceutically acceptable salt for use according to claim 23, wherein the autoimmune disease is multiple sclerosis. 
Spoj ili farmaceutski prikladna sol za uporabu prema zahtjevu 23, gdje je autoimuna bolest multipla skleroza.
The compound or pharmaceutically acceptable salt for use according to claim 26, wherein the further medicament is natalizumab, dimethyl fumarate, an interferon, or glatiramer acetate, optionally wherein the interferon is a pegylated interferon, a non-pegylated interferon, interferon β-1a or pegylated interferon β -1 a. 
Spoj ili farmaceutski prikladna sol za uporabu prema zahtjevu 26, gdje je dodatni lijek natalizumab, dimetil fumarat, interferon, ili glatiramer acetat, po izboru gdje je interferon pegilirani interferon, ne-pegilirani interferon, interferon β-1a ili pegilirani interferon β-1a.
or an ester, a protected compound at the amino on the ring in the 7-side chain, a pharmaceutically acceptable salt, or a solvate thereof. 
Spoj s formulom: [image] ili njegov ester, zaštićeni spoj na amino na prstenu u 7-bočnom lancu, njegova farmaceutski prihvatljiva sol, ili njegov solvat.
The compound, or an ester, a protected compound at the amino on the ring in the 7-side chain, a pharmaceutically acceptable salt, or a solvate thereof according to any one of claims 1-17, which is for treating an infectious disease. 
Spoj ili njegov ester, zaštićeni spoj na amino na prstenu u 7-bočnom lancu, njegova farmaceutski prihvatljiva sol, ili njegov solvat u skladu sa zahtjevom 1, naznačen time da je namijenjen upotrebi za liječenje zarazne bolesti.
A compound of the formula: or its ester, a protected compound at the amino on the ring in the 7-side chain, a pharmaceutically acceptable salt, or a solvate thereof. 
Spoj s formulom: [image] ili njegov ester, zaštićeni spoj na amino na prstenu u 7-bočnom lancu, njegova farmaceutski prihvatljiva sol, ili njegov solvat.
The compound or its ester, a protected compound at the amino on the ring in the 7-side chain, a pharmaceutically acceptable salt, or a solvate thereof according to claim 1, for use in treating an infectious disease. 
Spoj ili njegov ester, zaštićeni spoj na amino na prstenu u 7-bočnom lancu, njegova farmaceutski prihvatljiva sol, ili njegov solvat u skladu sa zahtjevom 1, naznačen time da je namijenjen upotrebi za liječenje zarazne bolesti.
is hydrogen; (C1-C4)alkyl optionally substituted with a hydroxy group or a (C1-C4)alkoxy group; or (C3-C6)cycloalkyl; 
je vodik; (C1-C4)alkil koji može biti supstituiran s hidroksilnom skupinom ili (C1-C4)alkoksilnom skupinom; ili (C3-C6)cikloalkil;
R2' is hydrogen; (C1-C4)alkyl optionally substituted with a (C1-C4)alkoxy; or a phenyl group, the phenyl group being optionally substituted with a (C1-C4)alkoxy group; 
’ je vodik; (C1-C4)alkil koji može biti supstituiran s (C1-C4)alkoksi; ili fenilnom skupinom, fenilna skupina koja može biti supstituirana s (C1-C4)alkoksi-skupinom;
is hydrogen; (C1-C4)alkyl optionally substituted with a hydroxy group or a (C1-C4)alkoxy group; 
je vodik; (C1-C4)alkil koji može biti supstituiran s hidroksilnom skupinom ili (C1-C4)alkoksilnom skupinom;
A compound of any one of claims 1 to 3, selected from: 
Spoj iz bilo kojeg od patentnih zahtjeva 1 do 3, odabran od sljedećih:
A compound of claim 5 which is 2-[2,2-difluoro-2-(3-butoxyphenyl)-ethylamino]-N,N-dimethyl-acetamide or a pharmaceutically acceptable salt thereof. 
Spoj iz patentnog zahtjeva 5 koji jest 2-[2,2-difluoro-2-(3-butoksifenil)-etilamino]-N,N-dimetil-acetamid ili odgovarajuća farmaceutski prihvatljiva sol.
A compound of any one of claims 1 to 7 for use as a medicament. 
Spoj iz bilo kojeg od patentnih zahtjeva 1 do 7 za upotrebu kao lijek.
A compound of any one of claims of 1 to 8 for use as a medicament active as sodium and/or calcium channel modulator against disorders caused by dysfunctions of voltage gated sodium and/or calcium channels. 
Spoj iz bilo kojeg od patentnih zahtjeva 1 do 8 za upotrebu kao lijek koji je aktivan kao modulator natrijevog i/ili kalcijevog kanala protiv poremećaja uzrokovanih disfunkcijama natrijevih i/ili kalcijevih kanala ovisnih o naponu.
A compound of claim 9 wherein the disorder caused by dysfunctions of voltage gated sodium and/or calcium channels is selected from neuropathic pain, chronic pain, acute pain, headaches, neurological conditions, neurogenerative disorders, cognitive disorders, psychiatric disorders, vertigo, tinnitus, muscle spasm, cardiovascular diseases, endocrine disorders involving excessive or hypersecretory or otherwise inappropriate cellular secretion of an endogenous substance, liver diseases, inflammatory processes affecting all body systems, disorders of the gastrointestinal (GI) tract, disorders of the genito-urinary tract, ophthalmic diseases and eating disorders. 
Spoj iz patentnog zahtjeva 9, naznačen time da je poremećaj uzrokovan disfunkcijama natrijevih i/ili kalcijevih kanala ovisnih o naponu odabran od sljedećih: neuropatska bol, kronična bol, aktuna bol, glavobolje, neurološka stanja, neurodegenerativni poremećaji, kognitivni poremećaji, psihijatrijski poremećaji, vrtogalvica, tinitus, mišićni spazam, kardiovaskularne bolesti, endokrini poremećaji koji obuhvaćaju prekomjerno ili hipersekrecijsko ili na drugi način neodgovarajuće stanično izlučivanje endogene tvari, bolesti jetre, upalni procesi koji djeluju na sve tjelesne sustave, poremećaji gastrointestinalnog trakta, poremećaji genito-urinarnog trakta, bolesti oka i poremećaji prehrane.
A compound of any one of claims 1 to 10 for use as a medicament for the treatment of neuropathic pain, chronic pain and/or acute pain. 
Spoj iz bilo kojeg od patentnih zahtjeva 1 do 10 za upotrebu kao lijek za liječenje neuropatske boli, kronične boli i/ili akutne boli.
A compound of any one of claims 1 to 10 for use as a medicament for the treatment of headaches. 
Spoj iz bilo kojeg od patentnih zahtjeva 1 do 10 za upotrebu kao lijek za liječenje glavobolja.
A compound of any one of claims 1 to 10 for use as a medicament for the treatment of neurological conditions. 
Spoj iz bilo kojeg od patentnih zahtjeva 1 do 10 za upotrebu kao lijek za liječenje neuroloških stanja.
A compound of claim 13, wherein the neurological condition is epilepsy. 
Spoj iz patentnog zahtjeva 13, naznačen time da neurološko stanje jest epilepsija.
A compound of any one of claims 1 to 10 for use as a medicament for the treatment of cognitive and/or psychiatric disorders. 
Spoj iz bilo kojeg od patentnih zahtjeva 1 do 10 za upotrebu kao lijek za liječenje kognitivnih i/ili psihijatrijskih poremećaja.
A pharmaceutical composition containing a compound of any one of claims 1 to 7 as active ingredient together with a pharmaceutically acceptable excipient. 
Farmaceutski pripravak koji sadrži kao aktivni sastojak spoj iz bilo kojeg od patentnih zahtjeva 1 do 7 zajedno s farmaceutski prihvatljivim ekscipijensom.
A package as claimed in Claim 1, wherein the fold line (19) is discontinuous and formed by cutting through the material of the sealing flap (5). 
Pakiranje u skladu sa patentnim zahtjevom 1 ili 2, naznačeno time što je linija (19) savijanja isprekidana i napravljena je presijecanjem kroz materijal brtvenog kapka (5).
A package as claimed in any one of Claims 1 to 5, wherein the connecting tab (16) of the sealing flap (5) is glued to a flap (18) of the lid (7). 
Pakiranje u skladu sa bilo kojim patentnim zahtjevom 1 do 5, naznačeno time što je spojni jezičac (16) brtvenog kapka (5) zalijepljen na preklop (18) poklopca (7).
A package as claimed in Claim 10, wherein the distance (D) between the fold line (19) and the re-stick glue (17b) on the sealing flap (5) is at least 1 mm. 
Pakiranje u skladu sa bilo kojim patentnim zahtjevom 1 do 9, naznačeno time što je udaljenost (D) između linije (19) savijanja i ljepila (17b) za višekratno lijepljenje na brtvenom kapku (5) najmanje 1 mm.
A pharmaceutical composition comprising compound of formula IIB: or a pharmaceutically acceptable salt, solvate, stereoisomer and/or ester thereof, wherein: 
Farmaceutski sastav koji sadrži spoj formule IIB: [image] Formula IIB ili njegovu farmaceutski prihvatljivu sol, solvat, stereoizomer i/ili ester, pri čemu:
and R21, taken together with the nitrogen atom to which they are attached, form an unsubstituted or substituted 5-6 membered heterocyclyl ring containing 1-2 heteroatoms selected from the group consisting of N and O; 
i R21, uzeti zajedno sa atomom dušika za koji su vezani, formiraju nesupstituirani ili supstituirani 5-6 člani heterociklični prsten koji sadrži 1-2 heteroatoma izabrana iz grupe koja se sastoji od N i O;
A compound of claim 1 having formula IIB, or a pharmaceutically acceptable salt, solvate, stereoisomer and/or ester thereof, wherein R13 is -(CH2)0-3CR17R18NR20R21, -(CH2)0-3CR17R18NR17C(O) NR20R21 or -(CH2)1-3-R23. 
Farmaceutski sastav prema patentnom zahtjevu 2, koji sadrži spoj formule IIB, ili njegovu farmaceutski prihvatljivu sol, solvat, stereoizomer i/ili ester, pri čemu R13 je-(CH2)0-3CR17R18NR20R21 ili-(CH2)0-3 CR17R18NR17C(O)-NR20R21.
Method for the preparation of the nanostructured organic-inorganic hybrid formulation of claim 8, characterized by comprising the following steps: 
Postupak za pripremu nanostrukturirane organsko-anorganske hibridne formulacije prema patentnom zahtjevu 8, naznačen time, da sadrži sljedeće stupnjeve:
hydrolyzing and condensing the mixture obtained in step a) with water, 
hidroliziranje i kondenziranje smjese dobivene u stupnju a) s vodom,